BioNTech SE Cash And Cash Equivalents
BioNTech SE (BNTX) had Cash And Cash Equivalents of EUR 7.68 billion as of 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Notes
ifrs-full:CashAndCashEquivalents · last filed 2026-03-10
- 2025-12-31: Cash And Cash Equivalents 7.68B EUR.
- 2024-12-31: Cash And Cash Equivalents 9.76B EUR.
- 2023-12-31: Cash And Cash Equivalents 11.66B EUR.
- 2022-12-31: Cash And Cash Equivalents 13.88B EUR.
| Period end | Cash And Cash Equivalents | Cash And Cash Equivalents as first filed |
|---|---|---|
| 2025-12-31 | 7.68B EUR 20-F · filed 2026-03-10 | |
| 2024-12-31 | 9.76B EUR 20-F · filed 2026-03-10 | |
| 2023-12-31 | 11.66B EUR 20-F · filed 2026-03-10 | |
| 2022-12-31 | 13.88B EUR 20-F · filed 2026-03-10 | |
| 2021-12-31 | 1.69B EUR 20-F · filed 2025-03-10 | |
| 2020-12-31 | 1.21B EUR 20-F · filed 2024-03-20 | 1.21B EUR 20-F · filed 2021-03-30 |
| 2019-12-31 | 519.10M EUR 20-F · filed 2023-03-27 | 519.15M EUR 20-F · filed 2020-03-31 |
| 2018-12-31 | 411.50M EUR 20-F/A · filed 2022-10-26 | 411.50M EUR 20-F · filed 2020-03-31 |
| 2017-12-31 | 172.11M EUR 20-F · filed 2021-03-30 | |
| 2016-12-31 | 303.68M EUR 20-F · filed 2020-03-31 |